Initial Focus On Metastatic Renal Cell Carcinoma

ArgosĀ“ lead oncology product, AGS-003, is initially being developed to treat metastatic renal cell carcinoma patients. Renal cell carcinoma, or RCC, is the most common type of kidney cancer. According to the American Cancer Society, or ACS, 2013 Cancer Facts and Figures Report, approximately 65,000 new cases of kidney cancer and nearly 14,000 deaths due to kidney cancer are expected in 2013 in the United States. The National Comprehensive Cancer Network, or NCCN, estimates that 90% of kidney cancer cases are RCC, and that 85% of these cases are classified as clear cell RCC. According to the NCDB, between 14-20% of newly diagnosed RCC cases in the US were stage IV or metastatic RCC at presentation between 2000-2011. Additionally, patients initially diagnosed with earlier stage, or non-metastatic, RCC may later progress to mRCC. We estimate, based on publicly available information, that the current worldwide mRCC market for approved targeted therapies exceeds $2 billion.

ArgosĀ“ primary focus is on cancer. Argos believes that its personalized immunotherapeutics are applicable to a wide range of cancers, including both solid tumor and hematologic malignancies, and infectious diseases.

> View Our Therapeutic Platforms